Concepedia

18-months relapse-free survival (RFS) and biomarker analyses of OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant (neoadj) ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma

Elisa A. Rozeman, Alexander M. Menzies, Oscar Krijgsman, Esmée P. Hoefsmit, Bart A. van de Wiel, Karolina Sikorska, Trieu My Van, Hanna Eriksson, Carolien Bierman, Michel González,

Annals of Oncology · 2019 · 20 citations · 0 references

DOI

Concepts